Peer-Reviewed Publication
Mayo Clin Proc Digit Health2026;4(1):100335.March 1, 2026Journal Article
Evaluation of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Incidental Pulmonary Nodules: The CREATE Study.
Deniz Koksal1, Arunkumar Govindarajan2, Hari Kishan Gonuguntla3, Sibel Nayci4, Ricardo Cordova5, Mohamed Helmy Zidan6, Susan McCutcheon7, Ashwini Saha8, Pushpalatha Kantharaju9, Sagar Sen10, Rohitashva Agrawal11, Laksmi Wulandari12,13
1Department of Chest Diseases, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
2Aarthi Scans and Labs, Chennai, India.
3Yashoda Hospitals, Hyderabad, India.
4Department of Chest Diseases, Mersin University Medical Faculty, Mersin, Turkey.
5Department of Radiology & Imaging, Instituto Mexicano del Seguro Social, Mexico.
6Chest Diseases Department, Faculty of Medicine, Alexandria University, Egypt.
7International Oncology, AstraZeneca, Switzerland.
8International Oncology-Lung Cancer, AstraZeneca, Malaysia.
9International Evidence Generation, Oncology, AstraZeneca, India.
10Operations and Program Management, Qure.ai, India.
11Clinical Department, Qure.ai, India.
12Department of Pulmonology and Respiratory Medicine, Dr Soetomo General Academic Hospital, Surabaya, Indonesia.
13Department of Pulmonology and Respiratory Medicine, Universitas Airlangga, Surabaya, Indonesia.
Abstract
OBJECTIVE: To evaluate the effectiveness of the artificial intelligence-based qXR lung nodule malignancy score (qXR-LNMS) in detecting high-risk incidental pulmonary nodules (IPNs) on chest X-rays (CXRs).
PATIENTS AND METHODS: The CREATE (NCT05817110), a prospective, observational study for participants aged 35 years or older with IPN (size, ≥8 to ≤30 mm) on CXR, enrolled 712 participants (high-r…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans